Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
or

Casi Pharmaceuticals Inc (CASI)

Casi Pharmaceuticals Inc (CASI)
2.36 +0.06 (+2.61%) 14:13 ET [NASDAQ]
2.20 x 1,900 2.30 x 100
Realtime by (Cboe BZX)
2.20 x 1,900 2.30 x 100
Realtime - - (-) -
Quote Overview for Thu, Mar 20th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
2.25
Day High
2.50
Open 2.26
Previous Close 2.30 2.30
Volume 14,017 14,017
Avg Vol 6,916 6,916
Stochastic %K 71.34% 71.34%
Weighted Alpha -47.58 -47.58
5-Day Change +0.29 (+14.01%) +0.29 (+14.01%)
52-Week Range 2.04 - 7.67 2.04 - 7.67
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 35,634
  • Shares Outstanding, K 15,493
  • Annual Sales, $ 33,880 K
  • Annual Income, $ -26,940 K
  • EBIT $ -30 M
  • EBITDA $ -26 M
  • 60-Month Beta 0.41
  • Price/Sales 1.45
  • Price/Cash Flow N/A
  • Price/Book 2.71

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 55.54%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.29
  • Growth Rate Est. (year over year) +344,582.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.04 +15.69%
on 03/14/25
Period Open: 2.46
2.50 -5.60%
on 03/20/25
-0.10 (-4.07%)
since 02/20/25
3-Month
2.04 +15.69%
on 03/14/25
Period Open: 2.65
3.47 -31.99%
on 12/26/24
-0.29 (-10.94%)
since 12/20/24
52-Week
2.04 +15.69%
on 03/14/25
Period Open: 3.11
7.67 -69.23%
on 09/11/24
-0.75 (-24.12%)
since 03/20/24

Most Recent Stories

More News
CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia

BEIJING, CHINA / ACCESSWIRE / January 6, 2025 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and...

CASI : 2.36 (+2.61%)
Nasdaq Futures Fall as Micron’s Sales Outlook Disappoints, U.S. GDP Data and Nike Earnings in Focus

September Nasdaq 100 E-Mini futures (NQU24) are trending down -0.23% this morning as an underwhelming sales forecast from chipmaker Micron weighed on sentiment, while investors awaited a flurry of U.S....

NQU24 : 19,808.01s (-0.21%)
MU : 102.79 (+0.72%)
FDX : 245.63 (-0.60%)
AAPL : 212.53 (-1.26%)
WHR : 94.22 (-0.30%)
MRNA : 32.93 (-1.17%)
NKE : 72.21 (-1.07%)
MKC : 80.54 (-0.98%)
WBA : 11.15 (-0.09%)
AYI : 266.70 (-0.10%)
HMB.S.DX : 136.950 (-0.33%)
LEVI : 15.70 (-2.36%)
CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATES

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and...

CASI : 2.36 (+2.61%)
Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and...

CASI : 2.36 (+2.61%)
CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman Islands incorporated biopharmaceutical company focused on developing and commercializing...

CASI : 2.36 (+2.61%)
CASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI) ("CASI" or the "Company"), a biopharmaceutical company focused on developing and commercializing...

CASI : 2.36 (+2.61%)
CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative...

CASI : 2.36 (+2.61%)
CASI PHARMACEUTICALS COMPLETES REDOMICILIATION MERGER

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI) ("CASI" or the "Company"), a biopharmaceutical company focused on developing and commercializing...

CASI : 2.36 (+2.61%)
CASI PHARMACEUTICALS AND CLEAVE THERAPEUTICS ANNOUNCE CLINICAL TRIAL APPLICATION APPROVAL FOR CB-5339 IN PATIENTS WITH MULTIPLE MYELOMA IN CHINA

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 2.36 (+2.61%)
CASI PHARMACEUTICALS' PARTNER JUVENTAS ANNOUNCES NEW DRUG APPLICATION FOR CNCT19 ACCEPTED BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 2.36 (+2.61%)
CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 2.36 (+2.61%)
CASI PHARMACEUTICALS ANNOUNCES EXIT OF JUVENTAS INVESTMENT TO STRENGTHEN BALANCE SHEET

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 2.36 (+2.61%)
CASI PHARMACEUTICALS AND BIOINVENT ANNOUNCE DOSING OF FIRST PATIENT IN BI-1206 PHASE 1 CLINICAL TRIAL FOR THE TREATMENT OF RELAPSED/REFRACTORY NON-HODGKIN'S LYMPHOMA IN CHINA

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 2.36 (+2.61%)
BINV : 34.07 (-1.62%)
CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 2.36 (+2.61%)
CASI PHARMACEUTICALS TO REPORT SECOND QUARTER 2022 FINANCIAL RESULTS AND HOST CONFERENCE CALL AUGUST 12, 2022

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 2.36 (+2.61%)
CASI PHARMACEUTICALS ANNOUNCES ITS PARTNER, PRECISION AUTOIMMUNE THERAPEUTICS CO., LTD HAS COMPLETED FIRST-ROUND FINANCING OF $21 MILLION

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 2.36 (+2.61%)
BioInvent and CASI Pharmaceuticals Announce CTA Approval for Clinical Studies of BI-1206 in NHL in China

LUND, SE / ACCESSWIRE / December 10, 2021 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) , a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory...

BINV : 34.07 (-1.62%)
CASI : 2.36 (+2.61%)
Pre-Market Brief: Stocks See Support from Dovish Chinese Policy News

Morning Markets Dec S&P 500 futures this morning are up by +0.21%. Stocks are seeing support from a rally in Chinese stocks today on signs that China’s central bank may soon ease monetary policy. In...

MRNA : 32.93 (-1.17%)
VG : 11.65 (+4.02%)
GFS : 37.80 (-2.05%)
CASI : 2.36 (+2.61%)
ASTR : 0.5390 (-2.00%)
ATVI : 94.42 (-0.05%)
PGNY : 21.74 (+0.14%)
AUPH : 8.34 (-0.36%)
CASI Pharmaceuti­­­cals Announces Partner Juventas Completion Of Series C Financing Of $63 Million (RMB410 Million) For Acceleration Of CNCT19 Pivotal Trials And Commercialization

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 2.36 (+2.61%)
Global Liver Cancer Therapeutics Market Size Is Forecasted To Grow To $1.148 Billion By 2026

Palm Beach, FL – August 24, 2021 – FinancialNewsMedia.com News Commentary – Recently, approximately 1.2 million new liver cancer cases have been reporting around the world. The increasing intense...

QBIO : 0.0001 (unch)
ABVC : 0.6659 (+0.89%)
TRIL : 18.44 (+2.62%)
CASI : 2.36 (+2.61%)
SESN : 12.5760 (+7.29%)

Business Summary

CASI Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the acquisition, development and commercialization of proprietary therapeutics for the treatment of cancer and other diseases for the global markets, with a focus on China. The Company's products present antiangiogenic...

See More

Key Turning Points

3rd Resistance Point 2.44
2nd Resistance Point 2.41
1st Resistance Point 2.35
Last Price 2.36
1st Support Level 2.27
2nd Support Level 2.25
3rd Support Level 2.19

See More

52-Week High 7.67
Fibonacci 61.8% 5.52
Fibonacci 50% 4.86
Fibonacci 38.2% 4.19
Last Price 2.36
52-Week Low 2.04

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Precision Trading with Bollinger Bands: Identifying Breakouts & Reversals